journal article·2022-12Open access

Fabrication of active targeting lipid nanoparticles: Challenges and perspectives

Ipshita Menon, Maryam Zaroudi, Yuanzhe Zhang, Elizabeth Aisenbrey, Liwei Hui

Abstract

Targeted drug and gene delivery is the key for precision therapy. Lipid nanoparticles as non-viral vectors have attracted extensive attentions in treating a variety of diseases, such as cancer, immune disease, cardiac diseases and pathogen infection. They exhibit low immunogenicity and low cytotoxicity, which make them as the most-commonly used vectors. More importantly, their surfaces could be functionalized, which provide a platform to improve targeting and pharmacokinetic/pharmacodynamic properties. Although there has been great success to synthesize lipid nanoparticles, it remains as a challenge to produce active targeting lipid nanoparticles especially with definable targetability, high quality and good translation reproducibility. This review focus on the techniques to fabricate active targeting lipid nanoparticles. We start with a brief introduction of targeting lipid nanoparticles, followed by a focused discussion of various preparation approaches including one-pot assembly and post-insertion functionalization. The methods, mechanism and representative examples are introduced, together with the comparison of their advantages and restrictions. Finally, challenges facing formulation screening and clinical translation are discussed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. What's next for the synthetic lethality drug discovery engine?10.1038/d41573-022-00107-0 ↗
2. Active targeting of nano-photosensitizer delivery systems for photodynamic therapy of cancer stem cells10.1166/jbn.2015.2090 ↗
3. Enhanced subcellular trafficking of resveratrol using mitochondriotropic liposomes in cancer cells10.3390/pharmaceutics11080423 ↗
4. A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells10.1016/j.mito.2019.07.005 ↗
5. Hyaluronic acid coated liposomes Co-delivery of natural cyclic peptide RA-XII and mitochondrial targeted photosensitizer for highly selective precise combined treatment of colon cancer10.2147/IJN.S311577 ↗
6. Curcumin-loaded liposomes with the hepatic and lysosomal dual-targeted effects for therapy of hepatocellular carcinoma10.1016/j.ijpharm.2021.120628 ↗
7. Nuclear targeted peptide combined with gambogic acid for synergistic treatment of breast cancer
8. Oxygen nanocarrier broke the hypoxia trap of solid tumors and rescued transfection efficiency for gene therapy10.1186/s12951-021-01144-4 ↗
9. Advocation and advancements of EPR effect theory in drug delivery science: a commentary10.1016/j.jconrel.2022.04.031 ↗
10. Brain-targeted drug delivery by manipulating protein corona functions10.1038/s41467-019-11593-z ↗
11. Development of a cancer vaccine using in vivo click-chemistry-mediated active lymph node accumulation for improved immunotherapy10.1002/adma.202006007 ↗
12. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery10.1016/j.jconrel.2021.11.022 ↗
13. EphA2-Receptor targeted PEGylated nanoliposomes for the treatment of BRAF(V600E) mutated parent- and vemurafenib-resistant melanoma10.3390/pharmaceutics11100504 ↗
14. The tangled history of mRNA vaccines10.1038/d41586-021-02483-w ↗
15. Current approaches of nanomedicines in the market and various stage of clinical translation10.1016/j.apsb.2022.02.025 ↗
16. Nanomedicine review: clinical developments in liposomal applications10.1186/s12645-019-0055-y ↗
17. Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy10.1039/D1BM01520F ↗
18. Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment10.1016/j.apsb.2021.07.019 ↗
19. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles10.1016/j.jconrel.2022.01.027 ↗
20. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques10.1038/s41591-021-01574-5 ↗
21. Smart and emerging nanomaterials-based biosensor for SARS-CoV-2 detection10.1016/j.matlet.2021.131092 ↗
22. Recent advancements of biogenic iron nanoparticles in cancer theranostics10.1016/j.matlet.2022.131769 ↗
23. Potentialities of nanomaterials for the management and treatment of metabolic syndrome: a new insight10.1016/j.mtadv.2021.100198 ↗
24. X-ray induced photodynamic therapy with copper-cysteamine nanoparticles in mice tumors10.1073/pnas.1900502116 ↗
25. The implications of recent advances in carboxymethyl chitosan based targeted drug delivery and tissue engineering applications10.1016/j.jconrel.2014.04.043 ↗
26. Biomedical applications of carboxymethyl chitosans10.1016/j.carbpol.2012.07.076 ↗
27. Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library10.1016/j.mcp.2015.04.001 ↗
28. Phage-display-guided nanocarrier targeting to atheroprone vasculature10.1021/acsnano.5b01048 ↗
29. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker10.1021/bc300498d ↗
30. Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding10.1016/j.ejps.2011.11.015 ↗
31. ALPPL2-Binding peptide facilitates targeted mRNA delivery for efficient hepatocellular carcinoma gene therapy
32. Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy10.1016/j.intimp.2021.108148 ↗
33. Mannose-modified liposome Co-delivery of human papillomavirus type 16 E7 peptide and CpG oligodeoxynucleotide adjuvant enhances antitumor activity against established large TC-1 grafted tumors in mice10.2147/IJN.S275670 ↗
34. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines10.1016/j.addr.2022.114417 ↗
35. Targeting strategies for tissue-specific drug delivery10.1016/j.cell.2020.02.001 ↗
36. An update on actively targeted liposomes in advanced drug delivery to glioma10.1016/j.ijpharm.2021.120645 ↗
37. Liposome surface modification by phospholipid chemical reactions10.1016/j.chemphyslip.2021.105084 ↗
38. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells10.1016/j.ijpharm.2017.06.003 ↗
39. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma10.1016/j.ejps.2018.07.055 ↗
40. Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel10.2147/IJN.S216432 ↗
41. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells10.1038/s41419-020-02939-3 ↗
42. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma10.1016/j.jconrel.2018.03.006 ↗
43. Comparison of three synthetic transferrin mimetic small peptides to promote the blood-brain barrier penetration of vincristine liposomes for improved glioma targeted therapy10.1016/j.ijpharm.2021.121395 ↗
44. Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells10.3390/molecules23020268 ↗
45. Tumor targeting DVDMS-nanoliposomes for an enhanced sonodynamic therapy of gliomas10.1039/C8BM01187G ↗
46. Near-infrared fluorescence imaging-guided focused ultrasound-mediated therapy against Rheumatoid Arthritis by MTX-ICG-loaded iRGD-modified echogenic liposomes10.7150/thno.44865 ↗
47. Liposomes with cyclic RGD peptide motif triggers acute immune response in mice10.1016/j.jconrel.2018.12.003 ↗
48. A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated10.1016/j.apsb.2020.07.024 ↗
49. Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity10.1016/j.jconrel.2020.01.040 ↗
50. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis10.1016/j.biomaterials.2017.10.053 ↗
51. Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy10.1039/C9BM01732A ↗
52. Dual targeting single arrow: neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis10.1016/j.ijpharm.2021.121022 ↗
53. Influences of galactose ligand on the uptake of TADF liposomes by HepG(2) cells10.1016/j.pdpdt.2020.102014 ↗
54. N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma10.1016/j.ejmech.2021.113605 ↗
55. Co-delivery of dihydroartemisinin and HMGB1 siRNA by TAT-modified cationic liposomes through the TLR4 signaling pathway for treatment of lupus nephritis10.2147/IJN.S220754 ↗
56. A peptide probe enables photoacoustic-guided imaging and drug delivery to lung tumors in K-ras(LA2) mutant mice10.1158/0008-5472.CAN-18-3089 ↗
57. Mitochondria-targeted cationic liposomes modified with alkyltriphenylphosphonium bromides loaded with hydrophilic drugs: preparation, cytotoxicity and colocalization assay10.1039/C9TB01853K ↗
58. Self-adjuvant effect by manipulating the bionano interface of liposome-based nanovaccines10.1021/acs.nanolett.1c01133 ↗
59. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil10.1016/j.ejps.2017.12.011 ↗
60. Ultrasound-targeted microbubble destruction augmented synergistic therapy of rheumatoid arthritis via targeted liposomes10.1039/D0TB00430H ↗
61. Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer10.1016/j.chemphyslip.2020.104882 ↗
62. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes10.2147/IJN.S153944 ↗
63. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways10.1016/j.jconrel.2018.08.015 ↗
64. Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes10.2147/IJN.S157019 ↗
65. Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery10.1016/j.bmcl.2020.127151 ↗
66. A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes10.1016/j.jconrel.2019.06.009 ↗
67. Hyaluronated and PEGylated liposomes as a potential drug-delivery strategy to specifically target liver cancer and inflammatory cells10.3390/molecules27031062 ↗
68. Chondroitin sulfate-modified liposomes for targeted Co-delivery of doxorubicin and retinoic acid to suppress breast cancer lung metastasis10.3390/pharmaceutics13030406 ↗
69. Efficient anti-glioma therapy through the brain-targeted RVG15-modified liposomes loading paclitaxel-cholesterol complex10.2147/IJN.S318266 ↗
70. Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: synthesis and biological evaluation10.1016/j.chemphyslip.2019.104785 ↗
71. Fluorescence imaging-guided multifunctional liposomes for tumor-specific phototherapy for laryngeal carcinoma10.1039/D0BM00249F ↗
72. Transferrin and folic acid co-modified bufalin-loaded nanoliposomes: preparation, characterization, and application in anticancer activity10.2147/IJN.S176012 ↗
73. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies10.2147/DDDT.S211168 ↗
74. Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery10.1088/1748-605X/ac6b73 ↗
75. Targeted treprostinil delivery inhibits pulmonary arterial remodeling10.1016/j.ejphar.2021.174700 ↗
76. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells10.1016/j.ejpb.2019.01.020 ↗
77. Microfluidic self-assembly of a combinatorial library of single- and dual-ligand liposomes for in vitro and in vivo tumor targeting10.1016/j.ejpb.2018.06.017 ↗
78. One-step microfluidic fabrication of multi-responsive liposomes for targeted delivery of doxorubicin synergism with photothermal effect10.2147/IJN.S329621 ↗
79. Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation10.1049/nbt2.12012 ↗
80. Zhou, J. E., et al.,Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. J. Contr. Release 343 (2022), pp 175-186.10.1016/j.jconrel.2022.01.038 ↗
81. Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate
82. Liposomes co-delivery system of doxorubicin and astragaloside IV co-modified by folate ligand and octa-arginine polypeptide for anti-breast cancer10.1039/C9RA09040A ↗
83. Targeted delivery of zoledronic acid through the sialic acid - siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - a promising cancer immunotherapy10.1016/j.ijpharm.2020.119929 ↗
84. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide10.1080/10717544.2018.1425777 ↗
85. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy10.1016/j.actbio.2021.07.063 ↗
86. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties10.2147/IJN.S215941 ↗
87. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma10.1016/j.jconrel.2019.06.033 ↗
88. Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes10.1016/j.brainres.2020.146738 ↗
89. In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA10.1016/j.nano.2020.102225 ↗
90. Dual-modified liposome for targeted and enhanced gene delivery into mice brain10.1124/jpet.119.264127 ↗
91. Targeted-delivery of siRNA via a polypeptide-modified liposome for the treatment of gp96 over-expressed breast cancer10.1016/j.msec.2020.111847 ↗
92. Evaluation of nanoscaled dual targeting drug-loaded liposomes on inhibiting vasculogenic mimicry channels of brain glioma
93. Glioma-targeted multifunctional nanoparticles to co-deliver camptothecin and curcumin for enhanced chemo-immunotherapy10.1039/D1BM01987B ↗
94. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals10.1016/j.jconrel.2022.03.047 ↗
95. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma
96. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery10.1016/j.jconrel.2017.04.006 ↗
97. Dual-targeting for brain-specific liposomes drug delivery system: synthesis and preliminary evaluation10.1016/j.bmc.2018.08.006 ↗
98. Lipid nanoparticle technologies for nucleic acid delivery: a nanoarchitectonics perspective10.1002/adfm.202203669 ↗
99. Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells
100. Sustainable technologies for liposome preparation10.1016/j.supflu.2020.104984 ↗